خواص دارویی و گیاهی

فلوکستین در بارداری

دارو

چگونه با تست ساده بیماری را تشخیص دهیم 9 تست

سیارک

برای ارسال نظر، لطفا وارد حساب خود شوید یا ثبت نام نمایید.

قرص lyrica

آزیترومایسین یکی از محبوب ترین ضد میکروب های موجود در بازار امروز است.

قرص آتورواستاتین بدون توجه به غذا 1 بار در روز مصرف می شود.

تتراسایکلین یک آنتی بیوتیک باکتریواستاتیک متعلق به گروه تتراسایکلین است.

وارفارین برای جلوگیری از تشکیل لخته های جدید در بدن استفاده می شود.

این دارو با کمک به بازگرداندن تعادل سروتونین در مغز کار می کند.

ویتامین ای (E) ویتامینی است که در چربی حل می‌شود.

یکی از خواص عناب ضد سرطان بودن آن است. ناب باعث ازدیاد ویتامین k در خون می‌شود

داروی بتامتازون، دگزامتازون، تریامسینولون، داروهای تزریقی کورتون دار هستند.

قبل از درمان کودک زیر 12 سال با آسپرین، با پزشک خود مشورت کنید.

ویتامین k نقش مهمی در سیستم انعقاد خون دارد.

ملیجنت، لیناگلیپتین یک داروی دیابت نوع 2 است

بسیاری از افراد با استفاده از امپرازول عوارض جانبی جدی ندارند.

متادون، یک ضد درد قوی و یکی از این مواد است.

دوز کاپتوپریل براساس وضعیت پزشکی شما و پاسخ به درمان است.

همچنین به بخش هشدار در زمان مصرف ترامادول مراجعه کنید

کنترل مناسب دیابت، ممکن است خطر ابتلا به حمله قلبی یا سکته مغزی را کاهش دهد

محصولات حاوی آهن مانند هماتینیک یک عامل مهم مسمومیت مرگبار در کودکان زیر 6 سال

شربت ضد سرفه دکسترومتورفان برای سرفه خشک با علل مختلف است

مصرف این دارو ها معمولا 1 روز قبل از درمان(تزریق) شروع می شود

ورم پستان به التهاب غده پستانی ، فارغ از دلیل آن اشاره دارد.

ماساژ درمانی یکی از گسترده ترین و موثرترین درمانهای جایگزین مورد استفاده

روش درمان یک شخص از طریق طب سوزنی حدود سه هزار سال سابقه دارد.

کلیه حقوق مادی و معنوی برای سایت سیارک محفوظ است.

2 روز قبل

4 روز قبل

7 روز قبل

قرص lyrica

1 هفته قبل

2 هفته قبل

3 هفته قبل

4 هفته قبل

1 ماه قبل

نام کاربری و یا ایمیل:

رمز عبور:

من را به خاطر بسپار

کاربر جدید هستم!

0 موضوعات داغ

داروی پرگابالین با نام تجاری لیریکا (Lyrica) دارویی خوراکی است که برای درمان صرع، درد عصبی، فیبرومیالژیا و اختلال اضطرابی عمومی استفاده می‌شود.

پرگابالین یک داروی تجویزی است. این دارو به سه شکل وجود دارد: کپسول، محلول و قرص آهسته رهش. همه شکلهای آن از طریق دهان مصرف می‌شوند. کپسول خوراکی پرگابالین با نام تجاری Lyrica موجود است. این شکل از دارو به صورت داروی ژنریک در دسترس نیست. کپسول خوراکی پرگابالین را باید به عنوان بخشی از یک درمان ترکیبی استفاده کرد. این بدان معنی است که ممکن است لازم باشد همراه با داروهای دیگری مصرف شود. پرگابالین یک ماده کنترل شده است. پزشک استفاده شما از این دارو را کنترل خواهد کرد.

کپسول پرگابالین برای درمان موارد زیر استفاده می‌شود:

پرگابالین متعلق به یک رده دارویی به نام ضد تشنج است. یک رده دارویی یک گروه از داروها است که عملکردی مشابه دارند. این داروها اغلب برای درمان بیماریهای مشابهی استفاده می‌شوند. عملکرد پرگابالین بطور دقیق شناخته نشده است. این باور وجود دارد که بوسیله آرام کردن اعصاب صدمه دیده یا بیش فعال که موجب ایجاد درد یا تشنج می‌شوند، عمل می‌کند.

کپسول خوراکی پرگابالین می‌تواند موجب سرگیجه، خواب آلودگی و تاری دید شود. ممکن است بر قابلیت تفکر، دیدن یا حرکت کردن اثر بگذارد. به هنگام مصرف این دارو، نباید رانندگی کنید از ماشین استفاده کنید یا کارهایی که نیازمند هوشیاری هستند انجام دهید تا زمانی که نحوه اثر این دارو را بدانید.

پرگابالین موجب عوارض جانبی دیگری هم می‌شود.

عوارض جانبی شایع پرگابالین می‌تواند شامل موارد زیر باشد:

اگر این عوارض خفیف باشد، ممکن است در عرض چند روز یا دو هفته از بین بروند. اگر شدیدتر بودند یا از بین نرفتند با پزشک یا داروساز خود صحبت کنید.

اگر عوارض جانبی جدی دارید با پزشک خود یا اورژانس تماس بگیرید. اگر علائم شما تهدید کننده زندگی هستند یا اگر وضعیت اورژانسی دارید با ۱۱۵ تماس بگیرید. عوارض جانبی حدی و علائم آنها ممکن است شامل موارد زیر باشند:

– واکنشهای آلرژیک شدید: این واکنشها ممکن است تهدید کننده زندگی باشند. علائم آن می‌تواند شامل موارد زیر باشد:

– افکار خودکشی یا واکنشها: علائم می‌تواند شامل موارد زیر باشد:

– مشکلات قلبی. علائم می‌تواند شامل موارد زیر باشد:

– خستگی و خواب آلودگی

قرص lyrica

کپسول خوراکی پرگابالین می‌تواند با داروهای دیگر، ویتامینها، یا داروهای گیاهی که در حال مصرف هستید، تداخل داشته باشد. تداخل وقتی بوجود می‌آید که یک ماده شیوه عملکرد دارو را تغییر می‌دهد. این موضوع می‌تواند مضر باشد یا از کارکرد صحیح دارو جلوگیری کند.

برای جلوگیری از تداخلات دارویی، پزشک شما باید همه داروهای شما را به دقت کنترل کند. حواستان باشد که به پزشکتان در مورد همه داروها، ویتامینها یا داروهای گیاهی که در حال مصرف هستید با پزشکتان صحبت کنید. برای اینکه بفهمید چطور این دارو ممکن است با چیزی که در حال مصرف هستید تداخل داشته باشد، با پزشک یا داروساز خود صحبت کنید.

نمونه‌هایی از داروها که می‌توانند با پرگابالین تداخل داشته باشند در زیر لیست شده‌اند.

مصرف پرگابالین با داروهای خاصی ممکن است موجب عوارض جانبی بیشتر شود. این داروها عبارتند از:

این دارو چندین هشدار دارد

این دارو موجب واکنش آلرژیک شدید می‌شود. علائم شامل موارد زیر است:

اگر دچار این علائم شدید با نزدیکترین مرکز درمانی خود تماس گرفته یا حضوری مراجعه کنید.

اگر هر کدام از واکنشهای آلرژیک را نسبت به آن داشتید، دوباره آن را مصرف نکنید. مصرف دوباره این دارو ممکن است کشنده باشد.

استفاده از نوشیدنیهای الکلی می‌تواند خطر خواب آلودگی و سرگیجه ناشی از پرگابالین را افزایش دهد. در هنگام مصرف این دارو نباید الکل مصرف کرد. اگر اهل مصرف الکل هستید با پزشک خود صحبت کنید.

افراد دارای مشکلات کلیوی: اگر مشکلات کلیه یا سابقه بیماری کلیه دارید ممکن است بدنتان قادر به پاک کردن کامل این دارو از بدن نباشد. این ممکن است سطح این دارو را افزایش دهد و موجب عوارض جانبی بیشتر شود. پزشک شما ممکن است یک دوز پایینتر را به شما بدهد تا به اجتناب از عوارض جانبی کمک شود.

برای افراد دارای مشکلات قلبی: اگر مشکلات قلبی دارید از جمله مشکلات متوسط تا سکته قلبی از پزشکتان بپرسید که آیا این دارو برای شما که مشکلات قلبی دارید بی خطر است یا نه. این دارو می‌تواند مشکل شما را بدتر کند. علائم بدتر شدن مشکلات قلبی را بدتر کند از جمله تورم بازوها، پاها، افزایش وزن و احتباس مایعات (تورم) در بدن.

افراد دارای افسردگی یا مشکلات ذهنی: اگر افسردگی یا مشکلات روحی روانی یا مشکلات رفتاری دارید، این دارو ممکن است خطر افکار و رفتارهای خودکشی را افزایش دهد. شما و خانواده‌تان باید برای بروز افسردگی جدید یا بدتر شدن آن، تغییرات غیر معمول در خلقیات و رفتار یا افکار صدمه زننده به خودتان را مراقب باشید.

برای افرادی با سابقه اعتیاد به مواد مخدر یا الکل: اگر در گذشته از دارو یا مواد مخدر یا الکل استفاده می‌کردید بگذارید پزشک شما هم این مورد را بداند. پرگابالین یک ماده کنترل شده است و استفاده از آن می‌تواند منجر به سو مصرف شود.

برای زنان باردار: اگر باردار هستید یا در حال اقدام برای بارداری هستید با پزشکتان گفتگو کنید. این دارو را باید در صورتی استفاده کنید که فواید آن نسبت به خطرات بالقوه آن قابل توجیه باشد. مطالعات حیوانی نشان داده است که دوزهای بالای پره گابالین باعث افزایش اثرات منفی روی جنین می‌شود. اگر در حین مصرف این دارو باردار شوید، با مسئول درمانی خود صحبت کنید.

زنان شیرده: پرگابالین از طریق شیر مادر در مقادیر کوچکی عبور می‌کند. به عبارت بهتر این ممکن است موجب عوارض جانبی در بچه‌ای شود که در حال شیر خوردن است. اگر در حال شیر دادن به بچه هستید با پزشک خود صحبت کنید. شما ممکن است لازم باشد تصمیم بگیرید که شیر دادن را متوقف کنید یا مصرف این دارو را.

برای مردانی که برای پدر شدن برنامه ریزی می‌کنند: تحقیقات حیوانی نشان داد که این دارو موجب تغییر اسپرم می‌شود و باعث باروری کمتر در حیوانات مذکر شد. همچنین نقصهای زایمان در نوزادان حیوانات اهلی که با این دارو درمان می‌شدند، دیده شد. معلوم نیست که آیا این مشکلات در افرادی که این دارو را مصرف می‌کنند اتفاق می‌افتد یا نه.

برای سالمندان: کلیه‌های شما ممکن است خیلی خوب کار نکنند. این می‌تواند موجب شود بدن شما دارو را به کندی پردازش کند. در نتیجه، مقدار بالاتری از یک دارو در بدن شما برای مدتی طولانی باقی بماند. این خطر عوارض جانبی را بالا می‌برد.

برای کودکان: این دارو در کودکان مطالعه نشده است. این دارو را نباید در بچه‌های زیر ۱۸ سال نباید استفاده کرد.

دوزهای دارو، شکل آن و نحوه مصرف آن بستگی به عوامل زیر دارد:

کپسول پرگابالین برای درمان طولانی مدت استفاده می‌شود. اگر این دارو را مطابق میزان تجویز شده مصرف نکنید می‌تواند خطرناک باشد.

اگر مصرف دارو را ناگهان متوقف کنید یا آن را همیشه مصرف نکنید: در یا تشنج از بین نمی‌رود یا بدتر می‌شود.

اگر یک دوز دارو را فراموش کنید یا طبق زمان بندی مصرف نکنید: دارو به خوبی عمل نخواهد کرد یا ممکن است بطور کامل متوقف شود. برای اینکه دارو عملکرد خوبی داشته باشد باید مقدار مشخصی را که بدن شما نیاز دارد در تمامی اوقات دستور داده شده مصرف شود.

اگر بیش از اندازه مصرف شود: در این صورت سطح خطرناکی از دارو در بدن شما وجود دارد. علائم آن شامل موارد زیر است:

اگر فکر می‌کنید این دارو را زیاد مصرف کردید، با پزشک خود یا مرکز کنترل مسمومیت تماس بگیرید. اگر علائم شما شدید است با اورژانس تماس بگیرید یا به نزدیکترین مرکز درمانی مراجعه کنید.

اگر مصرف یک نوبت دارو را فراموش کردید: همینکه آن را بخاطر آوردید، دارو را مصرف کنید. اما اگر چند ساعت قبل از نوبت بعدی به خاطر آوردید، تنها یک نوبت را مصرف کنید. هرگز مصرف دارو را دو برابر نکنید. این کار موجب عوارض جانبی خطرناک خواهد شد.

چگونه می‌توان از عملکرد دارو مطمئن شد: برای نوروپاتی محیطی، شینگل و درد عصبی ایجاد شده بوسیله آسیب نخاعی: شما باید سوزش، سوزن سوزن شدن یا درد ناخوشایند باید کاهش یابد

فیبرومیالژیا: درد کمتری را در کل بدنتان احساس خواهید کرد.

تشنج: تشنجهای شما باید بهتر کنترل شوند.

اگر پزشک برای شما پرگابالین تجویز کرد، این ملاحظات را بخاطر داشته باشید.

یک نسخه از این دارو قابل تجدید است. شما نیازی به نسخه جدید برای این دارو ندارید. پزشک شما تعداد مجاز خرید مجدد را در نسخه می‌نویسد.

به هنگام مصرف این دارو در مسافرت این نکات را در نظر داشته باشید:

شما و پزشکتان باید مشکلات سلامتی خاص را مدیریت کنید. این می‌تواند به شما کمک کند تا در هنگام مصرف این دارو خاطر جمع باشید. این مشکلات شامل موارد زیر است:

داروهای دیگری وجود دارد که مشکل شما را درمان می‌کنند. بعضی از آنها ممکن است برای شما بهتر از دیگران باشد. با پزشکتان در مورد داروهای دیگری که برای شما موثر هستند، صحبت کنید.

– پرگابالین کپسول خوراکی است که تنها با نام تجاری دارو در دسترس است. این شکل دارو به صورت یک داروی ژنریک در دسترس نیست. نام تجاری: Lyrica لیریکا

– پرگابالین به صورت کپسول، محلول و قرص آهسته رهش موجود است. همه شکلهای دارو خوراکی هستند.

– کپسول خوراکی پرگابالین برای درمان درد عصبی و فیبرومیالژیا استفاده می‌شود. همچنین برای تشنجهای جزئی به هنگامی که داروهای دیگر تشنج مصرف می‌شوند، استفاده می‌شود.

ترجمه اختصاصی توسط مجله قرمز

منبع: healthline

کپی شد

تازه‌های دنیای مد

داغ ترین بحث ها

تازه‌های سلامت

مقالات زیبایی

مقالات سلامت

مقالات آشپزی

مقالات تغذیه

سلامت

۱۲ مرداد ۱۳۹۸

۴ مرداد ۱۳۹۸

۲۷ تیر ۱۳۹۸

دنیای مد

۱۵ مرداد ۱۳۹۸

داغ ترین بحث ها

بیشتر دیده شده

398,970

288,587

270,095

کلیه حقوق مادی و معنوی متعلق به وب سایت مجله قرمز می‌باشد. بازنشر مطالب فقط با ذکر لینک مستقیم مجاز است.

لایریکا ممکن است تعدادی از سلول‌های لخته شده (پلاکت) در خون شما را کاهش دهد. بنابراین اگر کبودی و یا خونریزی غیر طبیعی داشتید با دکتر خود در میان بگذارید. امیدواریم از این مطلب استفاده کافی را برده باشید. خواهشمندیم درصورتیکه تجربه مصرف این دارو را داشته و دیدگاهی در این باره دارید با دیگر خوانندگان مجله “ستاره” در قسمت نظرات به اشتراک بگذارید.

کلیه حقوق وبسایت ستاره متعلق به شرکت تجارت الکترونیک ستاره است.

(S)-3-(Aminomethyl)-5-methylhexansäure (IUPAC)

N03AX16

Antiepileptikum

fest

186–188 °C[1]

قرص lyrica

Gefahr

Pregabalin ist ein Arzneistoff aus der Gruppe der Antikonvulsiva. Zugelassen ist es EU-weit seit 2004 zur Behandlung von neuropathischen Schmerzen, der Epilepsie sowie der generalisierten Angststörung (GAS).
Seit dem 1. Dezember 2014 sind in Deutschland Generika verfügbar.[3]

Pregabalin war 2009 auf Platz 12 der umsatzstärksten patentgeschützten Arzneimittel in Deutschland, mit einem Umsatz von ca. 220 Millionen Euro.[4]

Pregabalin ist ein Derivat der γ-Aminobuttersäure (GABA). Das Pregabalinmolekül ist ein Zwitterion mit einem isoelektrischen Punkt bei 7,4:[5]

In wässrigen Medien ist es bei pH-Werten unterhalb von 3,7 leicht löslich.

Bei der enantioselektiven Synthese von Pregabalin wird zunächst ausgehend von Isobutyraldehyd und Acrylnitril mehrstufig das Salz aus dem tert-Butylammonium-Kation und dem Anion 3-Cyano-5-methyl-3-hexenoat hergestellt, dessen C=C-Doppelbindung dann einer enantioselektiven Hydrierung unterworfen wird und (S)-3-Cyano-5-methylhexansäure liefert. Die Reduktion der Nitrilgruppe liefert dann Pregabalin.[6] Es gibt auch alternative Synthesen bei denen eine Racematspaltung der Schlüsselschritt ist.[6]

Der Wirkmechanismus von Pregabalin wurde erst vor wenigen Jahren entdeckt. Er unterscheidet sich von demjenigen der γ-Aminobuttersäure (GABA), denn Pregabalin wirkt nicht an den GABA-Rezeptoren, sondern die GABA-ähnliche Wirkung wird über andere Mechanismen hervorgerufen.

Pregabalin bindet im zentralen Nervensystem (ZNS) an eine Untereinheit von spannungsabhängigen Calcium-Kanälen vom P/Q-Typ, das bedeutet in den „Purkinje-Zellen“ des Cerebellum und als R-Typ „r“emaining VGCCs vorkommende spannungsgesteuerte Calciumkanälen (Abkürzung VGCCs für voltage-gated Ca2+ channels). Das Einströmen von Calcium in die Nervenendigung wird gedrosselt, so dass eine gesteigerte Freisetzung der Neurotransmitter Glutaminsäure, Noradrenalin und Substanz P normalisiert wird. Dieser Wirkansatz verbindet die so unterschiedlichen Anwendungsgebiete, neuropathischen Schmerz, generalisierte Angststörung und Epilepsie.

Pregabalin wird rasch resorbiert und hat eine geschätzte Bioverfügbarkeit von über 90 Prozent. Es wird so gut wie nicht metabolisiert und unverändert über die Nieren ausgeschieden. Die Plasmahalbwertszeit beträgt 6,3 Stunden.[7]

Pregabalin wird bei Erwachsenen zur Behandlung von Epilepsie (mit und ohne sekundäre Generalisierung), bei peripheren und zentralen neuropathischen Schmerzen (beispielsweise bei Diabetes mellitus, Gürtelrose, Fibromyalgie oder Rückenmarksverletzungen) und generalisierter Angststörung eingesetzt. Es ist in Tagesdosen von 150 bis 300 mg wirksam, eine Steigerung auf bis zu 600 mg pro Tag ist möglich. Die Einstellung der Dosierung erfolgt individuell.

Pregabalin ist in der Lage, Entzugssymptome bei Opiatabhängigkeit zu reduzieren,[8] und wird hierzu aufgrund der relativ einfachen Zugänglichkeit (oft auch über den Schwarzmarkt) von Opiatabhängigen bezogen und angewendet.

Einige Studien haben gezeigt, dass Pregabalin ebenfalls erfolgreich (als Off-Label-Therapie) bei der Behandlung der sozialen Phobie eingesetzt werden kann.[9]

Die Wirksamkeit konnte in Studien bei diabetischer Neuropathie, postherpetischer Neuralgie und nach Rückenmarkverletzung gezeigt werden.
In anderen Modellen zum neuropathischen Schmerz wurde die Wirksamkeit nicht untersucht. Pregabalin wurde in 10 kontrollierten klinischen Studien untersucht, bei zweimal täglicher Gabe bis zu 13 Wochen und bei dreimal täglicher Gabe bis zu 8 Wochen. Insgesamt waren die Sicherheits- und Wirksamkeitsprofile bei zweimaliger und bei dreimaliger Gabe ähnlich. In klinischen Studien über bis zu 12 Wochen wurde sowohl bei peripheren als auch zentralen neuropathischen Schmerzen eine Schmerzverringerung innerhalb der 1. Woche festgestellt und blieb während der gesamten Behandlungsperiode erhalten.

In kontrollierten klinischen Studien bei peripheren neuropathischen Schmerzen kam es bei 35 % der mit Pregabalin behandelten Patienten und bei 18 % der Patienten unter Placebo zu einer 50%igen Verbesserung des Schmerzscores. Unter den Patienten, bei denen es nicht zu Schläfrigkeit kam, kam es bei 33 % der mit Pregabalin behandelten Patienten zu einer derartigen Verbesserung und bei 18 % der Patienten unter Placebo. Bei den Patienten, bei denen es zu Schläfrigkeit kam, betrugen die Responder-Raten unter Pregabalin 48 % und 16 % unter Placebo.

In der kontrollierten klinischen Studie bei zentralen neuropathischen Schmerzen kam es bei 22 % der mit Pregabalin behandelten Patienten und 7 % der Patienten unter Placebo zu einer 50%igen Verbesserung des Schmerzscores.[10]

Pregabalin wurde in drei kontrollierten klinischen Studien sowohl bei zweimal täglicher als auch bei dreimal täglicher Gabe über jeweils 12 Wochen untersucht. Insgesamt war das Verträglichkeits- und Wirksamkeitsprofil bei zweimal und bei dreimal täglicher Gabe ähnlich. Eine Reduktion der Anfallshäufigkeit wurde innerhalb der ersten Woche beobachtet.[11]

Die Wirksamkeit und Sicherheit von Pregabalin als Zusatztherapie von Epilepsie wurden bei pädiatrischen Patienten unter 12 Jahren und Jugendlichen nicht nachgewiesen.
Die Nebenwirkungen, die in einer Studie zur Pharmakokinetik und Verträglichkeit unter Beteiligung von Patienten ab einem Alter von 3 Monaten bis 16 Jahren (n=65) beobachtet wurden, waren jenen, die bei Erwachsenen beobachtet wurden, ähnlich. Die Ergebnisse einer einjährigen unverblindeten Sicherheitsstudie unter Beteiligung von 54 pädiatrischen Epilepsiepatienten ab einem Alter von 3 Monaten bis 16 Jahren zeigen, dass die Nebenwirkungen Fieber und Infektionen der oberen Atemwege häufiger als in Studien bei Erwachsenen beobachtet wurden.
Monotherapie (neu diagnostizierte Patienten): In einer kontrollierten klinischen Studie über 56 Wochen wurde Pregabalin bei zweimal täglicher Gabe untersucht. Bezogen auf den Endpunkt einer sechsmonatigen Anfallsfreiheit zeigte Pregabalin im Vergleich zu Lamotrigin keine Nichtunterlegenheit. Pregabalin und Lamotrigin waren gleichermaßen sicher und gut verträglich.[12]

Pregabalin wurde in 6 kontrollierten Studien über einen Zeitraum von 4 bis 6 Wochen sowie in einer 8-wöchigen Studie mit älteren Patienten und in einer Langzeitstudie zur Rückfallprävention mit einer doppelblinden Rückfallpräventionsphase von 6 Monaten untersucht.
Eine Besserung der Symptome von generalisierten Angststörungen gemäß der Hamilton-Angst-Skala (HAM-A) wurde innerhalb der 1. Woche beobachtet. In kontrollierten klinischen Studien über 4 bis 8 Wochen zeigten 52 % der mit Pregabalin behandelten Patienten und 38 % der Patienten unter Placebo eine im Vergleich zu den Ausgangswerten mindestens 50%ige Verbesserung des HAM-A-Gesamt-Scores.[13]

Zu den häufigsten Nebenwirkungen zählen Schwindel, Müdigkeit, Benommenheit, nachlassende Aufmerksamkeit, Trunkenheitsgefühl, insbesondere zu Beginn der Behandlung. Des Weiteren kann es zu verschwommenem Sehen, Doppeltsehen, Gleichgewichtsstörungen, Erektionsstörungen, Ödemen und Erbrechen kommen. Eine Gewichtszunahme ist häufig. Gelegentliche Nebenwirkungen sind Muskelzucken, Muskelkrämpfe, Herzrhythmusstörungen, Kraftlosigkeit und Stürze. Selten auftretende Nebenwirkungen sind Schluckbeschwerden, hoher Blutzucker, Muskelschäden, Nierenversagen, Brustschmerzen und Veränderungen der Sicht (Tiefenwahrnehmung, Lichtblitze, optische Helligkeit).
Weitere Nebenwirkungen, die nach Markteinführung berichtet wurden und deren Häufigkeit nicht bestimmt werden kann, sind Herzmuskelschwäche (Herzinsuffizienz), Änderung der Aufnahme von elektrischen Veränderungen (EKG) des Herzens, die mit Herzrhythmusstörungen zusammenhängen, Flüssigkeit in der Lunge, Verlust des Bewusstseins, Krampfanfälle sowie Überempfindlichkeits- und allergische Reaktionen.

Nach Absetzen einer Pregabalin-Therapie wurden bei einigen Patienten zum Teil schwere Entzugs-Symptome festgestellt. Pregabalin sollte deshalb nicht plötzlich abgesetzt, sondern ausschleichend dosiert werden, da es sonst auch zu einer Häufung epileptischer Anfälle kommen kann. Benommenheit und Schläfrigkeit können vor allem bei älteren Patienten zu Stürzen führen.

Es bestehen Hinweise auf ein Abhängigkeitspotenzial von Pregabalin, entsprechende Berichte gibt es aus Deutschland[14][15][16] und Schweden.[17]
Die Fachinformationen wurden um den Hinweis erweitert: „Fälle von nicht bestimmungsgemäßem Gebrauch, Missbrauch und Abhängigkeit wurden berichtet. Bei Patienten mit Drogenmissbrauch in der Vorgeschichte ist Vorsicht geboten und der Patient sollte hinsichtlich Symptomen eines nicht bestimmungsgemäßen Gebrauchs, des Missbrauchs oder der Abhängigkeit von Pregabalin (…) überwacht werden.“

Der Wirkstoff Pregabalin kann die Wirkung von ZNS-dämpfenden Substanzen wie Lorazepam und Alkohol verstärken, bis hin zu Atemschwäche (respiratorischer Insuffizienz) und Koma. Er verstärkt vermutlich auch kognitive und grobmotorische Beeinträchtigungen nach Einnahme von Oxycodon.[18]

Eine gleichzeitige Verwendung von Pregabalin und oralen hormonellen Kontrazeptiva („Antibabypille“) ist möglich.

Es liegen keine Untersuchungen zur Anwendung bei Kindern und Jugendlichen unter 18 Jahren vor. Es kann deswegen nicht empfohlen werden, dass diese Personengruppen Pregabalin anwenden.[19]

Es gibt keine kontrollierten klinischen Studien zur Anwendung von Pregabalin bei schwangeren Frauen. Tierversuche lassen jedoch vermuten, dass möglicherweise Gefahren für den Fötus bestehen könnten. Pregabalin sollte deshalb in der Schwangerschaft nur angewendet werden, wenn es unbedingt notwendig ist.[19] Nach Angabe des Herstellers Pfizer ist die Anwendung bei Schwangerschaft ausgeschlossen, es wird explizit darauf hingewiesen, dass gebärfähige Frauen eine „wirksame Verhütungsmethode“ anwenden müssen.[20]

Durch die Einnahme von Pregabalin kann es zu Benommenheit und Schläfrigkeit kommen. Deshalb wird Patienten davon abgeraten, Auto zu fahren, komplexe Maschinen zu bedienen oder andere potenziell gefährliche Tätigkeiten auszuführen, solange nicht bekannt ist, ob die Fähigkeit zur Ausübung solcher Tätigkeiten beeinträchtigt wird.[19]

Generic Name: pregabalin (pre GAB a lin)Brand Names: Lyrica, Lyrica CR

Medically reviewed by Sophia Entringer, PharmD Last updated on Jan 5, 2019.

Lyrica (pregabalin) was originally FDA approved as an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses in the brain that cause seizures. Pregabalin also affects chemicals in the brain that send pain signals across the nervous system.

Lyrica is used to treat pain caused by fibromyalgia, or nerve pain in people with diabetes (diabetic neuropathy), herpes zoster (post-herpetic neuralgia), or spinal cord injury.

Lyrica may also be used for purposes not listed in this medication guide.

قرص lyrica

Lyrica can cause a severe allergic reaction. Stop taking this medicine and seek emergency medical help if you have hives or blisters on your skin, trouble breathing, or swelling in your face, mouth, or throat.

Some people have thoughts about suicide while taking Lyrica. Stay alert to changes in your mood or symptoms. Report any new or worsening symptoms to your doctor.

If you have diabetes or heart problems, call your doctor if you have weight gain or swelling in your hands or feet while taking Lyrica.

Do not stop using this medicine suddenly, even if you feel fine. Stopping suddenly may cause withdrawal symptoms.

Do not change your dose without your doctor’s advice. Tell your doctor if the medication does not seem to work as well in treating your condition.

You should not use Lyrica if you are allergic to pregabalin.

Tell your doctor if you have ever had:

a mood disorder, depression, or suicidal thoughts;

heart problems (especially congestive heart failure);

a bleeding disorder;

low levels of platelets in your blood;

kidney disease (or if you are on dialysis);

diabetes (unless you are taking pregabalin to treat diabetic neuropathy);

drug or alcohol addiction; or

a severe allergic reaction (angioedema).

Some people have thoughts about suicide while taking Lyrica. Your doctor will need to check your progress at regular visits. Your family or other caregivers should also be alert to changes in your mood or symptoms.

Follow your doctor’s instructions about taking seizure medication if you are pregnant. Seizure control is very important during pregnancy, and having a seizure could harm both mother and baby. Do not start or stop taking this medicine without your doctor’s advice, and tell your doctor right away if you become pregnant.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of pregabalin on the baby.

This medication can temporarily decrease sperm count and may affect fertility in men (your ability to have children). In animal studies, pregabalin also caused birth defects in the offspring of males treated with this medicine. However, it is not known whether these effects would occur in humans. Ask your doctor about your risk.

You should not breast-feed while using Lyrica unless suggested by your physician.

Do not give this medicine to a child without medical advice. Lyrica is not FDA approved for seizures in anyone younger than 4 years old.

Take Lyrica exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.

Take the medicine at the same time each day, with or without food.

Do not crush, chew, or break an extended-release tablet. Swallow it whole.

Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Do not stop using Lyrica suddenly, even if you feel fine, or you could have unpleasant withdrawal symptoms. Follow your doctor’s instructions about tapering your dose for at least 1 week before stopping completely.

Call your doctor if your symptoms do not improve, or if they get worse.

In case of emergency, wear or carry medical identification to let others know you take seizure medication.

Store at room temperature away from moisture, heat, and light.

Lyrica dosage information (in more detail)

Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Avoid drinking alcohol. It may increase certain side effects of Lyrica.

Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.

Lyrica can cause a severe allergic reaction. Stop taking this medicine and get emergency medical help if you have: hives or blisters on your skin; difficult breathing; swelling of your face, lips, tongue, or throat.

قرص lyrica

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, depression, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.

Call your doctor at once if you have:

vision problems;

skin sores (if you have diabetes);

easy bruising, unusual bleeding;

swelling in your hands or feet, rapid weight gain (especially if you have diabetes or heart problems); or

unexplained muscle pain, tenderness, or weakness (especially if you also have fever, unusual tiredness, or dark colored urine).

If you have diabetes, tell your doctor right away if you have any new sores or other skin problems.

Common Lyrica side effects may include:

dizziness, drowsiness;

swelling in your hands and feet;

trouble concentrating;

increased appetite;

weight gain;

dry mouth; or

blurred vision.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Lyrica side effects (in more detail)

Using Lyrica with other drugs that make you drowsy can worsen this effect. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.

Tell your doctor about all your other medicines, especially:

oral diabetes medicine – pioglitazone, rosiglitazone; or

an ACE inhibitor – benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, or trandolapril.

any other seizure medications

This list is not complete. Other drugs may interact with pregabalin, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Lyrica drug interactions (in more detail)

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Lyrica only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 1996-2019 Cerner Multum, Inc. Version: 8.01.

Medical Disclaimer

Other brands: Lyrica CR

Latest: FDA Approves First Generics of Lyrica

gabapentin, prednisone, clonazepam, amitriptyline, Cymbalta, duloxetine, lamotrigine, Lamictal, topiramate, Klonopin

Lyrica reviews

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 Aug 2019), Cerner Multum™ (updated 1 Aug 2019), Wolters Kluwer™ (updated 31 July 2019) and others.

Third Party Advertising

We comply with the HONcode standard for trustworthy health information – verify here

Copyright © 2000-2019 Drugs.com. All rights reserved.

Generic Name: pregabalin

Medically reviewed by Drugs.com. Last updated on Nov 3, 2018.

Note: This document contains side effect information about pregabalin. Some of the dosage forms listed on this page may not apply to the brand name Lyrica.

Common side effects of Lyrica include: infection, ataxia, blurred vision, constipation, diplopia, dizziness, drowsiness, fatigue, headache, peripheral edema, tremor, weight gain, visual field loss, accidental injury, and xerostomia. Other side effects include: abnormal gait, abnormality in thinking, amnesia, arthralgia, asthenia, cognitive dysfunction, confusion, edema, neuropathy, sinusitis, speech disturbance, vertigo, visual disturbance, myasthenia, amblyopia, increased appetite, and twitching. See below for a comprehensive list of adverse effects.

Applies to pregabalin: oral capsule, oral solution, oral tablet extended release

قرص lyrica

Along with its needed effects, pregabalin (the active ingredient contained in Lyrica) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pregabalin:

Some side effects of pregabalin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Applies to pregabalin: oral capsule, oral solution, oral tablet extended release

The most common adverse reactions to this drug are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and “thinking abnormal” (primarily difficulty with concentration/attention); the more commonly reported events in pediatric patients include increased weight and increased appetite.[Ref]

Very common (10% or more): Dizziness (up to 37%), somnolence (up to 25%)

Common (1% to 10%): Neuropathy, ataxia, vertigo, incoordination, tremor, abnormal gait, headache, speech disorder, twitching

Uncommon (0.1% to 1%): Syncope, stupor, myoclonus, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, hyporeflexia, hyperesthesia, burning sensation, ageusia, malaise

Rare (less than 0.1%): Convulsions, parosmia, hypokinesia, dysgraphia, shock, circumoral paresthesia, dysarthria, hyperalgesia, hyperkinesia, hypokinesia, hypotonia, myoclonus, neuralgia cerebellar syndrome, cogwheel rigidity, coma, dysautonomia, dystonia, encephalopathy, extrapyramidal syndrome, Guillain-Barre syndrome, hypalgesia, intracranial hypertension, torticollis, trismus, peripheral neuritis

Postmarketing reports: Coma[Ref]

Among pediatric patients receiving this drug for the treatment of partial onset seizures, somnolence was reported in 21% of drug treated patients and 14% of placebo patients, occurring more frequently at higher doses. Somnolence includes related terms of lethargy, sluggishness, and hypersomnia.

Patients treated for central neuropathic pain due to spinal cord injury have experienced an increased incidence of CNS adverse effects, especially somnolence. This may be due to an additive effect with concomitant medications.

There are postmarketing reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant agents.[Ref]

Very common (10% or more): Peripheral edema (up to 12%)

Common (1% to 10%): Chest pain

Uncommon (0.1% to 1%): Hypotension, hypertension, hot flushes, flushing, peripheral coldness, heart failure, postural hypotension, syncope

Rare (less than 0.1%): ST depressed, ventricular fibrillation

Frequency not reported: PR interval prolongation[Ref]

In controlled clinical trials in adult patients, peripheral edema was reported in 6% of patients receiving this drug compared with 2% in the placebo group; 0.5% and 0.2% of patients withdrew due to peripheral edema in the drug treated group and the placebo group, respectively.

Analyses of clinical trial ECG data has shown the mean PR interval increase was 3 to 6 msec at doses greater than or equal to 300 mg/day. Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or those taking other PR prolonging medications, although the number of patients in the study was not sufficient to draw a definitive conclusion.[Ref]

Common (1% to 10%): Confusion, euphoria, amnesia, nervousness, irritability, disorientation, insomnia, libido decreased, disturbance in attention, anxiety, depersonalization, stupor, abnormal thinking

Uncommon (0.1% to 1%): Cognitive disorder, mental impairment, abnormal dreams, agitation, apathy, aphasia, hallucinations, hostility

Rare (less than 0.1%): Delirium, delusions, manic reaction, paranoid reaction, personality disorder, psychotic depression, schizophrenic reaction, sleep disorder, disinhibition[Ref]

Uncommon (0.1% to 1%): Hypersensitivity

Rare (0.01% to 0.1%): Allergic reaction, anaphylactic reaction[Ref]

Symptoms of angioedema have included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There have also been reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Therapy should be discontinued immediately in patients with these symptoms. Caution is recommended if this drug is used in patients who have had a previous episode of angioedema. Patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE inhibitors]) may be at increased risk of developing angioedema.[Ref]

Common (1% to 10%): Ecchymosis, pruritus

Uncommon (0.1% to 1%): Angioedema, rash papular, urticaria, hyperhidrosis, abscess, cellulitis, alopecia, dry skin, eczema, hirsutism, skin ulcer, urticaria, vesiculobullous rash

Rare (less than 0.1%): Stevens Johnson syndrome, cold sweat, angioedema, exfoliative dermatitis, lichenoid dermatitis, melanosis, nail disorder, petechial rash, purpuric rash, pustular rash, skin atrophy, skin necrosis, skin nodule, subcutaneous nodule[Ref]

Common (1% to 10%): Dry mouth, constipation, nausea, vomiting, diarrhea, flatulence, abdominal distention, gastroenteritis

Uncommon (0.1% to 1%): Gastroesophageal reflux disease, salivary hypersecretion, hypoesthesia oral, cholecystitis, cholelithiasis, colitis, dysphagia, esophagitis, gastritis, GI hemorrhage, melena, mouth ulceration, pancreatitis, rectal hemorrhage, tongue edema

قرص lyrica

Rare (less than 0.1%): Ascites, granuloma

Postmarketing reports: Reduced lower gastrointestinal function events (e.g., intestinal obstruction, paralytic ileus, constipation)[Ref]

Postmarketing reports of reduced lower gastrointestinal function events have been reported when co-administered with medications that have the potential to produce constipation, such as opioids.[Ref]

Common (1% to 10%): Urinary incontinence, erectile dysfunction, impotence, urinary frequency, urinary incontinence

Uncommon (0.1% to 1%): Sexual dysfunction, ejaculation delayed, dysmenorrhea, breast pain, anorgasmia, albuminuria, dysuria, hematuria, kidney calculus, leukorrhea, menorrhagia, metrorrhagia, oliguria, urinary retention, urine abnormality, abnormal ejaculation, albuminuria, amenorrhea, dysmenorrhea, kidney calculus, menorrhagia, metrorrhagia, oliguria

Rare (less than 0.1%): Breast discharge, breast enlargement, gynecomastia, pelvic pain, balanitis, bladder neoplasm, cervicitis, dyspareunia, epididymitis, glomerulitis, ovarian disorder[Ref]

Uncommon (0.1% to 1%): Neutropenia, blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, blood creatinine increased, blood potassium decreased, deep thrombophlebitis

Rare (less than 0.1%): White blood cell count decreased, anemia, eosinophilia, hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocytopenia

Rare (0.01% to 0.1%): Myelofibrosis, polycythemia, prothrombin decreased, purpura[Ref]

Very common (10% or more): Infection (up to 14%)

Common (1% to 10%): Influenza syndrome[Ref]

Common (1% to 10%): Myasthenia, muscle cramp, arthralgia, back pain, pain in limb, cervical spasm, leg cramps

Uncommon (0.1% to 1%): Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness, neck rigidity, arthrosis

Rare (less than 0.1%): Rhabdomyolysis, chondrodystrophy, generalized spasm[Ref]

Very common (10% or more): Visual field changes (13%)

Common (1% to 10%): Blurry vision, abnormal vision, diplopia, conjunctivitis

Uncommon (0.1% to 1%): Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, photosensitivity reaction, dry eye, lacrimation increased, eye irritation, retinal vascular disorder, abnormality of accommodation, blepharitis, dry eyes, eye hemorrhage, hyperacusis, photophobia, retinal edema

Rare (0.01% to 0.1%): Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness, anisocoria, blindness, corneal ulcer, exophthalmos, extraocular palsy, iritis, keratitis, keratoconjunctivitis, miosis, mydriasis, night blindness, ophthalmoplegia, optic atrophy, papilledema, parosmia, ptosis, uveitis[Ref]

Common (1% to 10%): Asthenia, accidental injury, face edema, pain, otitis media, tinnitus

Uncommon (less than 0.1% to 1%): Generalized edema, pain, pyrexia, chills, thirst

Rare (0.01% to 0.1%): Retroperitoneal fibrosis, retinal vascular disorder, taste loss, taste perversion

Frequency not reported: Withdrawal effects following rapid discontinuation[Ref]

Some patients have reported withdrawal effects following abrupt/rapid discontinuation. These symptoms included insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea.[Ref]

There are postmarketing reports of respiratory failure and coma in patients taking pregabalin (the active ingredient contained in Lyrica) and other CNS depressant agents.[Ref]

Common (1% to 10%): Dyspnea, bronchitis, nasopharyngitis

Uncommon (0.1% to 1%): Epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness

Rare (less than 0.1%): Pulmonary edema, throat tightness, apnea, atelectasis, bronchiolitis, hiccup, laryngismus, lung fibrosis, yawn

Postmarketing reports: Respiratory failure[Ref]

Common (1% to 10%): Weight gain, edema, hypoglycemia, increased appetite

Uncommon (0.1% to 1%): Weight decreased, blood glucose increased

Rare (0.01% to 0.1%): Glucose tolerance decreased, urate crystalluria[Ref]

Uncommon (0.1% to 1%): Nephritis

Rare (0.01% to 0.1%): Acute kidney failure, pyelonephritis[Ref]

Postmarketing reports: Gynecomastia, breast enlargement

1. “Product Information. Lyrica (pregabalin).” Pfizer U.S. Pharmaceuticals Group, New York, NY.

2. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0

3. Cerner Multum, Inc. “Australian Product Information.” O 0

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer

Other brands: Lyrica CR

Latest: FDA Approves First Generics of Lyrica

gabapentin, prednisone, clonazepam, amitriptyline, Cymbalta, duloxetine, lamotrigine, Lamictal, topiramate, Klonopin

Lyrica reviews

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Third Party Advertising

We comply with the HONcode standard for trustworthy health information – verify here

Copyright © 2000-2019 Drugs.com. All rights reserved.

Generic Name: pregabalin (Oral route)

pre-GA-ba-lin

Medically reviewed by Drugs.com. Last updated on Nov 7, 2018.

In the U.S.

Available Dosage Forms:

قرص lyrica

Therapeutic Class: Neuropathic Pain Agent

Chemical Class: Gamma Aminobutyric Acid (class)

Pregabalin is used with other medicines to help control partial seizures (convulsions) in the treatment of epilepsy in patients 4 years of age and older. This medicine will not cure epilepsy and will only work to control seizures for as long as you continue to take it.

Pregabalin is also used for postherpetic neuralgia (pain that occurs after shingles) and pain caused by nerve damage from diabetes or a spinal cord injury.

Pregabalin capsule and oral liquid are also used to treat a condition called fibromyalgia (muscle pain and stiffness).

Pregabalin works in the central nervous system (CNS) to control seizures and pain. It is an anticonvulsant and neuropathic pain agent.

This medicine is available only with your doctor’s prescription.

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Appropriate studies have not been performed on the relationship of age to the effects of pregabalin in children younger than 4 years of age for partial onset seizures. Safety and efficacy have not been established for other conditions.

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of pregabalin in the elderly. However, elderly patients are more likely to have unwanted effects (eg, dizziness, blurred vision, confusion, or clumsiness) and age-related kidney problems, which may require an adjustment in the dose for patients receiving pregabalin.

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

This section provides information on the proper use of a number of products that contain pregabalin. It may not be specific to Lyrica. Please read with care.

Take this medicine exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of side effects.

This medicine should come with a Medication Guide. Read and follow these instructions carefully. Read it again each time you refill your prescription in case there is new information. Ask your doctor if you have any questions.

Pregabalin capsule or oral liquid may be taken with or without food.

Take the extended-release tablet after an evening meal. Swallow it whole. Do not crush, break, or chew it.

Measure the oral liquid using a marked measuring spoon, oral syringe, or medicine cup. The average household teaspoon may not hold the right amount of liquid.

The dose of this medicine will be different for different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

If you miss a dose of the extended-release tablet after your evening meal, take it before bedtime after a snack. If you miss the dose before bedtime, take it after your morning meal. If you do not take the dose the following morning, then take the next dose at your regular time after your evening meal. Do not take 2 doses at the same time.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

It is very important that your doctor check your progress at regular visits, especially for the first few months that you take pregabalin. This is necessary to allow for dose adjustments and to check for any unwanted effects.

This medicine may cause serious allergic reactions, including angioedema. These can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals after using this medicine.

Check with your doctor before using this medicine with alcohol or other medicines that affect the central nervous system (CNS). The use of alcohol or other medicines that affect the CNS with pregabalin may worsen the side effects of this medicine, such as dizziness, poor concentration, drowsiness, unusual dreams, and trouble with sleeping. Some examples of medicines that affect the CNS are antihistamines or medicine for allergies or colds, sedatives, tranquilizers, or sleeping medicines, medicine for depression, medicine for anxiety, prescription pain medicine or narcotics, medicine for attention deficit and hyperactivity disorder, medicine for seizures or barbiturates, muscle relaxants, or anesthetics, including some dental anesthetics.

This medicine may cause some people to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts or to become more depressed. If you or your caregiver notice any of these side effects, tell your doctor right away.

Pregabalin may cause blurred vision, double vision, clumsiness, unsteadiness, dizziness, drowsiness, or trouble with thinking. Do not drive or do anything else that could be dangerous until you know how this medicine affects you. If these side effects are especially bothersome, check with your doctor.

قرص lyrica

This medicine may cause you or your child to have edema (body swelling) or to gain weight. This may cause problems for people with heart failure. Talk with your doctor if you have concerns.

This medicine may increase your or your child’s risk for cancer (eg, hemangiosarcoma) and bleeding. Talk to your doctor if you have concerns.

Do not suddenly stop taking pregabalin without checking first with your doctor. Your doctor may want you or your child to gradually reduce the amount you are taking before stopping it completely. Stopping the medicine suddenly may cause seizures or side effects such as dizziness, diarrhea, nausea, headaches, vomiting, irritability, trouble with sleeping, nightmares, or tingling feelings.

Call your doctor if you or your child have any unexplained muscle pain, tenderness, or weakness, especially with a fever. These may be symptoms of a serious muscle problem called myopathy.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common

Rare

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Lyrica side effects (in more detail)

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 2019 Truven Health Analytics, Inc. All Rights Reserved.

Medical Disclaimer

Other brands: Lyrica CR

Latest: FDA Approves First Generics of Lyrica

gabapentin, prednisone, clonazepam, amitriptyline, Cymbalta, duloxetine, lamotrigine, Lamictal, topiramate, Klonopin

Lyrica reviews

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Third Party Advertising

We comply with the HONcode standard for trustworthy health information – verify here

Copyright © 2000-2019 Drugs.com. All rights reserved.

Generic Name: PregabalinClass: Anticonvulsants, Miscellaneous
VA Class: CN900
Chemical Name: (S)-3-(aminomethyl)-5-methylhexanoic acid
Molecular Formula: C8H17NO2
CAS Number: 148553-50-8

Medically reviewed by Drugs.com. Last updated on Oct 3, 2018.

Anticonvulsant; structurally related to the inhibitory CNS neurotransmitter GABA; also possesses analgesic activity.1 2 3 5 6 8 18

Management (in combination with other anticonvulsants) of partial seizures in adults.1 2 3 4 12

Management of postherpetic neuralgia (PHN) in adults.1 5 6

قرص lyrica

Management of pain associated with diabetic peripheral neuropathy (DPN) in adults.1 7 8

Management of fibromyalgia in adults.1 17 18 19 20

Closely monitor for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression.14 15 21 22 (See Suicidality Risk under Cautions.)

If pregabalin is discontinued, gradually taper dosage over ≥1 week.1 (See Discontinuance, Abuse Potential, and Dependence under Cautions.)

Administer capsules and oral solution orally without regard to meals.22

Pregabalin oral solution contains 20 mg of pregabalin per milliliter and prescriptions should be written in milligrams (mg).22 The pharmacist should calculate the applicable dose in mL for dispensing (e.g., 150 mg equals 7.5 mL of oral solution).22

Initially, 75 mg twice daily or 50 mg 3 times daily (initial dosage not to exceed 150 mg daily).1 2 3 12 Increase dosage up to a maximum of 600 mg daily, based on individual patient response and tolerability.1 2 3 4 12

Effective maintenance dosage is 150–600 mg daily, administered in 2 or 3 divided doses.1 2 3 4 12

Efficacy and adverse effects dose related,1 2 3 although effect of dosage escalation rate on tolerability not studied.1 10

Dosage recommendations for use of pregabalin in conjunction with gabapentin not available, since such regimens not evaluated in controlled clinical studies.1

Initially, 150 mg daily (75 mg twice daily or 50 mg 3 times daily).1 5 Increase dosage to 300 mg daily within 1 week based on efficacy and tolerability.1 5

Recommended maintenance dosage is 150–300 mg daily in 2 or 3 divided doses.1 6

May increase dosage up to 600 mg daily (administered in 2 or 3 divided doses) in those who tolerate the drug but do not experience adequate pain relief following 2–4 weeks of treatment with pregabalin 300 mg daily.1 5

Because of risk for dose-dependent adverse effects and higher rates of treatment discontinuance secondary to adverse effects, reserve dosages exceeding 300 mg daily for those who have continuing pain and are tolerating the 300-mg daily dosage.1

Initially, 150 mg daily in 3 divided doses (50 mg 3 times daily); increase dosage within 1 week up to a maximum of 300 mg daily (administered in 3 divided doses), based on efficacy and tolerability.1 7 8

Higher pregabalin dosages (i.e., 600 mg daily) provide no additional benefit, but may increase risk of adverse effects.1 7

Initially, 150 mg daily (75 mg twice daily).1 Increase dosage to 300 mg daily (150 mg twice daily) within 1 week based on efficacy and tolerability.1

Recommended maintenance dosage is 300–450 mg daily.1

May increase dosage up to a maximum of 450 mg daily (225 mg twice daily) in those who do not experience adequate benefit with pregabalin 300 mg daily.1

Higher pregabalin dosages (i.e., 600 mg daily) provide no additional benefit, but may increase risk of adverse effects.1

Maximum 600 mg daily.1

Maximum 450 mg daily.1

Modify dosage of pregabalin in adults with renal impairment (Clcr <60 mL/minute) based on Clcr.1

Usual Dosage Regimen (for Patients with Clcr of ≥60 mL/min)

Clcr (mL/min)

Adjusted Dosage Regimen

150 mg daily given in 2 or 3 divided doses

30–60

75 mg daily given in 2 or 3 divided doses

15–30

25–50 mg daily given as a single dose or in 2 divided doses

<15

25 mg once daily

قرص lyrica

300 mg daily given in 2 or 3 divided doses

30–60

150 mg daily given in 2 or 3 divided doses

15–30

75 mg daily given as a single dose or in 2 divided doses

<15

25–50 mg once daily

450 mg daily given in 2 or 3 divided doses

30–60

225 mg daily given in 2 or 3 divided doses

15–30

100–150 mg daily given as a single dose or in 2 divided doses

<15

50–75 mg once daily

600 mg daily given in 2 or 3 divided doses

30–60

300 mg daily given in 2 or 3 divided doses

15–30

150 mg daily given as a single dose or in 2 divided doses

<15

75 mg once daily

Patients undergoing hemodialysis should receive a supplemental dose immediately following each 4-hour dialysis session.1 Individuals receiving the 25-mg once-daily dosage regimen should receive a supplemental dose of 25 or 50 mg, those receiving the 25- to 50-mg once-daily dosage regimen should receive a supplemental dose of 50 or 75 mg, those receiving the 50- to 75-mg once-daily dosage regimen should receive a supplemental dose of 75 or 100 mg, and those receiving the 75-mg once-daily dosage regimen should receive a supplemental dose of 100 or 150 mg.1

Adjust dosage for geriatric patients with renal impairment.1 (See Renal Impairment under Dosage and Administration.)

Hypersensitivity to pregabalin or any ingredient in the formulation.1

Angioedema, including life-threatening angioedema with respiratory compromise requiring emergency treatment, reported during postmarketing surveillance in patients receiving initial and chronic pregabalin therapy.1 Specific symptoms included swelling of the face, mouth (e.g., tongue, lips, gums), and neck (e.g., throat, larynx).1 Discontinue pregabalin immediately in patients with these symptoms.1

Use with caution in patients who have had a previous episode of angioedema.1

Patients receiving other drugs associated with angioedema (e.g., ACE inhibitors) may be at increased risk of developing angioedema.1

Hypersensitivity reactions (i.e., skin redness, blisters, hives, rash, dyspnea, wheezing) reported during postmarketing surveillance in patients shortly after initiation of pregabalin therapy.1 Discontinue pregabalin immediately in patients with these symptoms.1

Abrupt withdrawal may result in increased seizure frequency; withdraw pregabalin gradually and reduce dosage slowly over ≥1 week.1

Following abrupt withdrawal, possible insomnia, nausea, headache, or diarrhea; suggestive of physical dependence.1

Possible euphoria.1 12

Although pregabalin is not known to be active at receptor sites associated with drugs of abuse, the Drug Enforcement Administration (DEA) placed the drug into schedule V of the Federal Controlled Substances Act (CSA) of 1970 subsequent to a recommendation for control from the Department of Health and Human Services (DHHS).1 9 12

Evaluate patients for history of drug abuse and observe them for signs of pregabalin misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behavior).1

Increased risk of suicidality (suicidal ideation or behavior) observed in an analysis of studies using various anticonvulsants, including pregabalin, in patients with epilepsy, psychiatric disorders (e.g., bipolar disorder, depression, anxiety), and other conditions (e.g., migraine, neuropathic pain); risk in patients receiving anticonvulsants (0.43%) was approximately twice that in patients receiving placebo (0.24%).14 15 21 22 Increased suicidality risk was observed ≥1 week after initiation of anticonvulsant therapy and continued through 24 weeks.14 15 22 Risk was higher for patients with epilepsy compared with those receiving anticonvulsants for other conditions.14 15 22

Closely monitor all patients currently receiving or beginning anticonvulsant therapy for changes in behavior that may indicate emergence or worsening of suicidal thoughts or behavior or depression.14 15 21 22 Anxiety, agitation, aggression, mania, and insomnia may be precursors to emerging suicidality.14

Balance risk of suicidality with the risk of untreated illness.14 22 Epilepsy and other illnesses treated with anticonvulsants are themselves associated with morbidity and mortality and an increased risk of suicidality.14 22 If suicidal thoughts or behavior emerge during anticonvulsant therapy, consider whether these symptoms may be related to the illness itself.21 22 (See Advice to Patients.)

Risk of edema (mainly peripheral edema).1 Peripheral edema not associated with deterioration of renal or hepatic function.1

No apparent association between peripheral edema and cardiovascular complications (e.g., hypertension, CHF) in patients without clinically important heart or peripheral vascular disease.1

Use with caution in patients with NYHA class III or IV CHF.1

Risk of dizziness and somnolence during pregabalin treatment.1

Possible weight gain related to dosage and duration of exposure to pregabalin, but not related to baseline body mass index (BMI), gender, age, or existing edema.1

Weight gain not associated with clinically important short-term changes in BP, but long-term cardiovascular effects not known.1

Pregabalin therapy does not appear to be associated with loss of glycemic control.1

Carcinogenicity (e.g., hemangiosarcoma) demonstrated in animals.1

New or worsening of preexisting tumors reported in humans; causal relationship not established.1

Possible blurred vision, decreased visual acuity, visual field changes, and funduscopic changes.1 Clinical importance not known.1

If visual disturbance persists, consider further or more frequent ocular assessment in those already monitored for ocular conditions.1

Possible increases in CPK concentrations (≥ 3 times the ULN) and rhabdomyolysis; causal relationship not established.1

Discontinue pregabalin if myopathy is diagnosed or suspected or if markedly elevated CPK concentrations occur.1

Risk of thrombocytopenia, although increased bleeding not reported.1

Risk of prolongation of the PR interval (mean increase: 3–6 msec) in those receiving daily pregabalin dosages of ≥ 300 mg.1 It appears that patients with preexisting PR prolongation at baseline or those receiving drugs that prolong the PR interval are not at increased risk for developing prolongation of the PR interval.1

Category C.1

North American Antiepileptic Drug (NAAED) Pregnancy Registry (for patients) at 888-233-2334 or [Web].22

Effect of pregabalin on labor and delivery not known.1 22

Distributed into milk in rats; not known whether distributed into human milk.1 Discontinue nursing or the drug because of potential risk to nursing infants.1

Safety and efficacy not established in children <18 years of age.1 10

No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.1 Neurologic adverse reactions including dizziness, blurred vision, balance disorder, tremor, confusional state, abnormal coordination, and lethargy occurred more frequently in patients ≥65 years of age than in younger adults in controlled clinical studies of patients with fibromyalgia.1

Substantially eliminated by kidneys; risk of increased severe adverse reactions in those with impaired renal function.1

Adjust dosage in those with renal impairment.1 (See Renal Impairment under Dosage and Administration.)

Concomitant use of pregabalin with other anticonvulsants for partial seizures: Dizziness,1 2 3 4 12 somnolence,1 2 3 4 12 ataxia,1 2 3 4 12 abnormal thinking,1 4 12 tremor,1 2 3 confusion,1 twitching,1 myoclonus,1 11 12 amnesia,1 speech disorder,1 incoordination,1 2 abnormal gait,1 dry mouth,1 2 12 constipation,1 increased appetite,1 weight gain,1 2 3 4 12 peripheral edema,1 12 blurred vision,1 2 3 12 diplopia,1 3 4 abnormal vision,1 accidental injury,1 2 pain.1

Management of postherpetic neuralgia: Dizziness,1 5 6 somnolence,1 5 6 headache,1 5 6 confusion,1 5 abnormal thinking,1 ataxia,1 5 incoordination,1 amnesia,1 abnormal gait,1 dry mouth,1 5 6 constipation,1 flatulence,1 vomiting,1 weight gain,1 peripheral edema,1 5 6 edema,1 facial edema,1 blurry vision,1 diplopia,1 abnormal vision,1 infection,1 6 flu syndrome,1 accidental injury,1 pain.1

Management of pain associated with diabetic peripheral neuropathy: Dizziness,1 7 8 somnolence,1 7 8 asthenia,1 7 8 neuropathy,1 7 ataxia,1 7 vertigo,1 abnormal thinking,1 confusion,1 7 euphoria,1 7 8 incoordination,1 dry mouth,1 7 constipation,1 7 8 flatulence,1 8 weight gain,1 peripheral edema,1 7 8 edema,1 hypoglycemia,1 accidental injury,1 7 8 back pain,1 chest pain,1 blurry vision,1 7 dyspnea.1

Management of fibromyalgia: Dizziness,1 somnolence,1 headache,1 euphoric mood,1 attention disturbance,1 balance disorder,1 memory impairment,1 confusional state,1 abnormal coordination,1 hypoesthesia,1 lethargy,1 tremor,1 anxiety,1 disorientation,1 depression,1 dry mouth,1 constipation,1 vomiting,1 flatulence,1 abdominal distention,1 weight gain,1 fatigue,1 peripheral edema,1 chest pain,1 abnormal feeling,1 edema,1 fluid retention,1 drunk feeling,1 increased appetite,1 blurred vision,1 sinusitis,1 vertigo,1 pharyngolaryngeal pain,1 arthralgia,1 muscle spasms,1 back pain.1

Does not appear to inhibit CYP isoenzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 or induce CYP1A2 or 3A4.1 10

Since pregabalin undergoes negligible metabolism in humans, pharmacokinetics unlikely to be affected by other agents through metabolic interactions.1

Increased metabolism of concomitantly administered CYP1A2 substrates (e.g., caffeine, theophylline) or CYP3A4 substrates (e.g., midazolam, testosterone) not anticipated.1

Does not bind to plasma proteins; pharmacokinetic interaction with drugs that are highly protein bound unlikely.1

Drug

Interaction

Comments

ACE inhibitors

Potential increased risk of developing angioedema22

Alcohol

Pharmacokinetic interaction unlikely.1 Possible additive effects on cognitive and gross motor functioning; no clinically important effects on respiration1

Avoid alcohol1

Anticonvulsants

Pharmacokinetic interaction unlikely with anticonvulsants (e.g., carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate)1

Possible slight decrease of rate of absorption of pregabalin when used concomitantly with gabapentin; pharmacokinetic interactions affecting gabapentin unlikely1

Pharmacokinetic interactions affecting pregabalin unlikely with tiagabine 1

Antidiabetic agents

Pharmacokinetic interactions affecting pregabalin unlikely with glyburide, insulin, or metformin1

Potential increased risk of weight gain and peripheral edema with thiazolidinediones1

Use thiazolidinediones with caution1

CNS depressants (e.g., opiates, benzodiazepines)

Possible additive adverse CNS effects (e.g., somnolence)22

Furosemide

Pharmacokinetic interactions affecting pregabalin unlikely with furosemide 1

Lorazepam

Pharmacokinetic interaction unlikely1

Possible additive effects on cognitive and gross motor functioning; no clinically important effects on respiration1

Oral contraceptives

Pharmacokinetic interaction unlikely1

Oxycodone

Pharmacokinetic interaction unlikely1

Possible additive effects on cognitive and gross motor functioning; no clinically important effects on respiration1

Well absorbed following oral administration.22 Peak plasma concentrations attained within 1.5 hours following oral administration of pregabalin capsules.22

Oral bioavailability is ≥90% and independent of dose.1

Food reduces peak plasma concentration by about 25–30% and delays time to peak plasma concentration by about 3 hours, but does not affect extent of absorption.1

Distributed into milk in rats; not known whether distributed into human milk.1

Crosses the placenta in rats; not known whether crosses the placenta in humans.1

Distributed into CSF in animals.1

Negligibly metabolized.1 18

Primarily excreted in urine, mainly as unchanged drug (90%).1 18

Mean: 6.3 hours.1

Pregabalin clearance tends to decrease with increasing age.1 (See Geriatric Use under Cautions and see Renal Impairment under Dosage and Administration.)

Removed by hemodialysis; dosage adjustment is necessary.1 (See Renal Impairment under Dosage and Administration.)

25°C (may be exposed to 15–30°C).1

25°C (may be exposed to 15–30°C).22 Can be used for up to 45 days after first opening the bottle (but not beyond expiration date).22

Exact mechanism of anticonvulsant and analgesic action unknown; may be related to binding with high affinity to the α2-δ subunit (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues.1 2 3 5 6 7 8 18

In vitro, reduces calcium-dependent release of several neurotransmitters, including glutamate, norepinephrine, calcitonin gene-related peptide, and substance P, possibly by modulation of calcium channel function.1 2 3 4 6 7 8 18

Does not bind directly to GABAA, GABAB, or benzodiazepine receptors; does not augment GABAA responses in cultured neurons; and does not alter brain concentrations of GABA in rats or affect GABA uptake or degradation.1 2 18 In cultured neurons, prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport.1 18

Does not block sodium channels; not active at opiate receptors; does not alter cyclooxygenase activity.1

Inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.1

Importance of adhering to prescribed directions for use and not altering the anticonvulsant regimen without first consulting with the clinician.14 15 22 Importance of providing copy of written patient information (medication guide) each time pregabalin is dispensed, and importance of reading this information prior to taking pregabalin.14 22

Risk of suicidality (anticonvulsants, including pregabalin, may increase risk of suicidal thoughts or actions in about 1 in 500 people).14 15 21 22 Importance of patients, family, and caregivers being alert to day-to-day changes in mood, behavior, and actions and immediately informing clinician of any new or worrisome behaviors (e.g., talking or thinking about wanting to hurt oneself or end one’s life, withdrawing from friends and family, becoming depressed or experiencing worsening of existing depression, becoming preoccupied with death and dying, giving away prized possessions).14 15 22

Risk of angioedema (e.g., swelling of the face, mouth [e.g., tongue, lips, gums], and neck [e.g., throat, larynx] with or without life-threatening respiratory compromise) and other hypersensitivity reactions (e.g., wheezing, dyspnea, rash, hives, blisters); importance of discontinuing the drug and reporting suggestive manifestations (e.g., edema of face, eyes, lips, or tongue; swallowing or breathing with difficulty) to a clinician.22 Concomitant administration with an ACE inhibitor may increase such risk.22

Risk of dizziness, somnolence, blurred vision, and other neuropsychiatric effects.1 Avoid driving or operating machinery or engaging in other hazardous activities while taking pregabalin until experienced with the drug’s effects.1

Avoid alcohol-containing beverages or products; drug may potentiate impairment of motor skills and sedation associated with ingestion of alcohol.1

Risk of visual disturbances.1 Importance of informing clinician if changes in vision occur.1

Importance of not discontinuing pregabalin abruptly, since insomnia, nausea, headache, or diarrhea may occur.1

Risk of edema and weight gain; concomitant administration with a thiazolidinedione antidiabetic agent may increase such risk.1 In patients with preexisting cardiac conditions, risk of heart failure may be increased.1

Importance of patients promptly informing clinicians of any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.1

Advise diabetic patients to watch for skin damage while receiving pregabalin therapy, since increased risk of skin ulcerations associated with pregabalin therapy has been observed in animal studies.1

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.22 Importance of clinicians informing women about the existence of and encouraging enrollment in pregnancy registries (see Pregnancy under Cautions).22

Advise patients of male-mediated teratogenicity.1 Importance of men informing clinicians if they plan to father a child.1

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1 Potential for additive CNS effects if used concomitantly with other CNS depressants (e.g., opiates, benzodiazepines).1

Importance of informing patients of other important precautionary information.1 (See Cautions.)

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Subject to control under the Federal Controlled Substances Act of 1970 as a schedule V (C-V) drug.1 9 12 (See Discontinuance, Abuse Potential, and Dependence under Cautions.)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

25 mg

Lyrica (C-V)

Pfizer

50 mg

Lyrica (C-V)

Pfizer

75 mg

Lyrica (C-V)

Pfizer

100 mg

Lyrica (C-V)

Pfizer

150 mg

Lyrica (C-V)

Pfizer

200 mg

Lyrica (C-V)

Pfizer

225 mg

Lyrica (C-V)

Pfizer

300 mg

Lyrica (C-V)

Pfizer

Solution

20 mg/mL

Lyrica (C-V)

Pfizer

1. Pfizer, Inc. Lyrica (pregabalin) capsules prescribing information. New York, NY; 2007 Jun.

2. French JA, Kugler AR, Robbins JL et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003; 60:1631-7. http://www.ncbi.nlm.nih.gov/pubmed/12771254?dopt=AbstractPlus

3. Arroyo S, Anhut H, Kugler AR et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004; 45:20-7. http://www.ncbi.nlm.nih.gov/pubmed/14692903?dopt=AbstractPlus

4. Beydoun A, Uthman BM, Kugler AR et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005; 64:475-80. http://www.ncbi.nlm.nih.gov/pubmed/15699378?dopt=AbstractPlus

5. Dworkin RH, Corbin AE, Young JP et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60:1274-83. http://www.ncbi.nlm.nih.gov/pubmed/12707429?dopt=AbstractPlus

6. Sabatowski R, Gálvez R, Cherry DA et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004; 109:26-35. http://www.ncbi.nlm.nih.gov/pubmed/15082123?dopt=AbstractPlus

7. Lesser H, Sharma U, LaMoreaux L et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004; 63:2104-10. http://www.ncbi.nlm.nih.gov/pubmed/15596757?dopt=AbstractPlus

8. Rosenstock J, Tuchman M, LaMoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004; 110:628-38. http://www.ncbi.nlm.nih.gov/pubmed/15288403?dopt=AbstractPlus

9. Department of Justice, Drug Enforcement Administration. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005; 70:43633-5. http://www.ncbi.nlm.nih.gov/pubmed/16050051?dopt=AbstractPlus

10. Pfizer, Morris Plains, NJ: Personal communication.

11. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001; 42:790-2. http://www.ncbi.nlm.nih.gov/pubmed/11422338?dopt=AbstractPlus

12. Anon. Drugs for epilepsy. Med Lett Treat Guid. 2005; 3:75-82.

14. Food and Drug Administration. FDA Alert: Information for healthcare professionals: suicidality and antiepileptic drugs. Rockville, MD; 2008 Jan 31. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm

15. Food and Drug Administration. FDA News: FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications. Rockville, MD; 2008 Jan 31. From the FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116847.htm

16. Pfizer Inc. Lyrica (pregabalin) capsules prescribing information. New York, NY; 2009 Apr.

17. Crofford LJ, Mease PJ, Simpson SL et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008; 136:419-31. http://www.ncbi.nlm.nih.gov/pubmed/18400400?dopt=AbstractPlus

18. Lyseng-Williamson KA, Siddiqui MA. Pregabalin : a review of its use in fibromyalgia. Drugs. 2008; 68:2205-23. http://www.ncbi.nlm.nih.gov/pubmed/18840008?dopt=AbstractPlus

19. . Pregabalin (Lyrica) for fibromyalgia. Med Lett Drugs Ther. 2007; 49:77-8. http://www.ncbi.nlm.nih.gov/pubmed/17878888?dopt=AbstractPlus

20. Arnold LM, Russell IJ, Diri EW et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008; 9:792-805. http://www.ncbi.nlm.nih.gov/pubmed/18524684?dopt=AbstractPlus

21. Food and Drug Administration. Suicidal behavior and ideation and antiepileptic drugs: update 5/5/2009. Rockville, MD; 2009 May 5. From the FDA website. Accessed 2009 Oct 21. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm

22. Pfizer Inc. Lyrica (pregabalin) capsules and oral solution prescribing information. New York, NY; 2009 Dec.

Medical Disclaimer

Other brands: Lyrica CR

Latest: FDA Approves First Generics of Lyrica

gabapentin, prednisone, clonazepam, amitriptyline, Cymbalta, duloxetine, lamotrigine, Lamictal, topiramate, Klonopin

Lyrica reviews

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Third Party Advertising

We comply with the HONcode standard for trustworthy health information – verify here

Generic name: PREGABALIN 25mgDosage form: capsule, oral solution

Medically reviewed by Drugs.com. Last updated on Jun 26, 2019.

LYRICA is given orally with or without food.

When discontinuing LYRICA, taper gradually over a minimum of 1 week [see Warnings and Precautions (5.3)].

قرص lyrica

Because LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function [see Dosage and Administration (2.7)].

The maximum recommended dose of LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional significant benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 300 mg/day is not recommended [see Adverse Reactions (6.1)].

The recommended dose of LYRICA is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day, and who are able to tolerate LYRICA, may be treated with up to 300 mg two times a day, or 200 mg three times a day (600 mg/day). In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, reserve dosing above 300 mg/day for those patients who have on-going pain and are tolerating 300 mg daily [see Adverse Reactions (6.1)].

The recommended dosages for adults and pediatric patients 1 month of age and older are included in Table 1. Administer the total daily dosage orally in two or three divided doses as indicated in Table 1. In pediatric patients, the recommended dosing regimen is dependent upon body weight. Based on clinical response and tolerability, dosage may be increased, approximately weekly.

Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related.

The effect of dose escalation rate on the tolerability of LYRICA has not been formally studied.

The efficacy of adjunctive LYRICA in patients taking gabapentin has not been evaluated in controlled trials. Consequently, dosing recommendations for the use of LYRICA with gabapentin cannot be offered.

The recommended dose of LYRICA for fibromyalgia is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 450 mg/day is not recommended [see Adverse Reactions (6.1)].

The recommended dose range of LYRICA for the treatment of neuropathic pain associated with spinal cord injury is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate LYRICA may be treated with up to 300 mg two times a day [see Clinical Studies (14.5)].

In view of dose-dependent adverse reactions and since LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function. The use of LYRICA in pediatric patients with compromised renal function has not been studied.

Base the dose adjustment in patients with renal impairment on creatinine clearance (CLcr), as indicated in Table 2. To use this dosing table, an estimate of the patient’s CLcr in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation:

Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CLcr greater than or equal to 60 mL/min). Then refer to Table 2 to determine the corresponding renal adjusted dose.

(For example: A patient initiating LYRICA therapy for postherpetic neuralgia with normal renal function (CLcr greater than or equal to 60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CLcr of 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.)

For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function. In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see Table 2).

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Other brands: Lyrica CR

Latest: FDA Approves First Generics of Lyrica

gabapentin, prednisone, clonazepam, amitriptyline, Cymbalta, duloxetine, lamotrigine, Lamictal, topiramate, Klonopin

Lyrica reviews

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more.

Third Party Advertising

We comply with the HONcode standard for trustworthy health information – verify here

Sie tablet sich lyrica registrierenum Beiträge zu for. Wenn Sie bereits Nutzer sind, melden Sie sich bitte an. Pregabalin Used Entzug nach Kurzzeiteinnahme – Übelkeit?! Ich habe gegen durch Burnout ausgelöste Schlaf- und Angststörung Lyrica used verschrieben bekommen und dieses für ca. Da Lyrica bei mir jedoch for nur sehr starke Kopfschmerzen, sondern ein permanentes Gefühl “neben mir zu stehen” sowie viele weitere Nebenwirkungen hatte, habe ich es langsam ausgeschlichen indem tablets die Kapseln aufgebrochen und deren Inhalt immer weiter reduziert habe erst halbiert, dann lyrica, geviertelt India hat aripiprazol abilify gut funktioniert und ich konnte seit meiner aller letzten Dosis vor einer Woche sogar Nächte durchschlafen.

Ich habe zwar wieder einige Beschwerden, die seit dem Absetzen zurückgekehrt sind oder durch den Entzug ausgelöst wurden – alles in allem geht es mir jedoch besser und lyrica fühle mich wohler als während der Tablet.

Nun plagt mich jedoch seit ein paar Tagen eine Übelkeit, die mehrmals täglich ohne bestimmten Grund auftritt und dann wieder verschwindet sowie nicht häufig aber doch ein Gefühl es würde tablets über used Kopfhaut streichen in etwa so, als wenn einem ein Käfer über das Haar am Kopf krabbelt. Können dies noch immer Auswirkungen des Pregabalinentzugs sein? Ich hatte vor einer Woche von einer viermalig eingenommenen 18mg Dosis auf 0mg gewechselt – eigentlich müsste das Medikament den Used doch bereits verlassen haben?

Oder hat der Wirkstoff bereits nach einer so kurzen Einnahme dazu geführt, dass die Neurotransmitterausschüttung “umprogramiert” wurde und sich india neurologischen Prozesse for erst lyrica müssen? Wie lange muss ich in diesem Fall noch mit Entzugserscheinungen rechnen?

Kapseln darf man nie zerbrechen und aufteilen, im Gegenteil zu Tabletten. Einen Tablettenentzug niemals alleine machen! Hallo, ich habe auch Lyrica genommen und keinerlei Entzug beim langsamen ausschleichen mit Arztbegleitung gehabt. Ich habe das Zeugs fast ein Jahr genommen. Den Unfug mit den Kapseln aufmachen und dann immer weniger Je nach Kapselart ist die Retardierung damit aufgehoben und es kann schwerste Vergiftungen zur Folge haben.

قرص lyrica

Im leichtesten Fall nur Wirkungslosigkeit. Wie du auf die mit Verlaub bescheuerte Idee gekommen bist, ist mir echt voltaren suppository for fever, nachdem dein Text mit Fachbegriffen gespickt ist.

Es gibt nur wenige Kapseln, die man aufmachen und auflösen kann, um sie z. For, auch ich habe Lyrica nehmen müssen. Morgens 75 und India 75mg wegen einer cervikalen Myelopathie. Ich durfte die Tabletten von jetzt auf gleich absetzen und hatte keine Probleme. Von Retardkapseln halte ich nichts.

Kläre wirklich mit Deinem Arzt ab ob Du sie absetzen darfst oder auf eine leichtere Dosierung umstellen kannst in Tablettenform z. Bitte kläre unbedingt mit deinem Arzt ab, ob die die Kapseln zerbrechen darfst for allen Tabletten steht dies in Beipackzettel. Bei vielen Trimox ist ein Zerteilen verboten, da die Hülle den Zeitpunkt tablet Resorption bestimmt früher oder später im Treating.

Wenn ich mich recht erinnere ist Lyrica ein retardiertes Medikament. Das bedeutet, dass used Tablette über einen gewissen Zeitraum seine Wirkung entfaltet. Wenn du nun nur den Inhalt ohne Cialis dosage instructions schluckst lyrica der ganze Wirkstoff auf einmal frei gesetzt.

Lasse dir das am besten noch einmal vom Arzt oder Pharmazeuten erklären ob ich alles richtig wiedergegeben habe. Die Lyrica Tablette zu halbieren ist auf jeden Fall lyrica gute Idee. Hi, ich kenne das mit den Entzugserscheinungen sehr gut. Pain war das für mich eine beschlossene Sache. Und das ist das, tablet gerade sehr sensible Menschen abhängig werden lässt. Ich war in for Blase. Es ist wirklich wie ein Schutz empfunden worden. Jetzt nehme ich seit fast einem Jahr used nichts mehr.

Ich konnte dank Lyrica mich vollkommen “normal” unter Menschen bewegen. Keine Panik, kein Herzrasen und Gedankenkreisen. Lyrica hat mich komplett ausgenockt. Ich habe damals mg eingenommen und unvernünftig wie ich bin, einfach von jetzt auf gleich abgesetzt.

Die ersten Wochen waren die Hölle. Die Entzugserscheinungen sind bei Lyrica wirklich extrem. Stärker als bei Benzos. Ich kann jedem nur empfehlen es langsam und kontrolliert ausschleichen zu lassen.

%PDF-1.6
%
247 0 obj
>
endobj

264 0 obj
>/Filter/FlateDecode/ID[]/Index[247 39]/Info 246 0 R/Length 87/Prev 267150/Root 248 0 R/Size 286/Type/XRef/W[1 2 1]>>stream
hbbd“b`N1@i2`@+e